Avtor/Urednik | Kenda, Miran F | |
Naslov | Practical guidelines for the use of ACE inhibitors | |
Tip | članek | |
Vir | In: Štiblar-Martinčič D, Petrovič D, editors. Cardiovascular diseases. Proceedings of the 32nd memorial meeting devoted to professor Janez Plečnik, International symposium in memory of professor Rene Favaloro; 2001 Dec 6-8; Ljubljana. Ljubljana: Medical faculty, | |
Leto izdaje | 2001 | |
Obseg | str. 115-23 | |
Jezik | eng | |
Abstrakt | Surveys of prescribing in both hospitals and primary care have shown delays in translating improved survival data from clinical trials into clinical practice thereby denying patients the benefits of proven treatments, such as the angiotensin-converting enzyme inhibitors. This may be due to unfamiliarity with clinical guidelines and concerns about adverse effects. Angiotensinconverting enzyme inhibitors are indicated in the treatment of all patients with heart failure, hypertension and in prevention of atherosclerosis. A number of landmark randomized, controlled trials have demonstrated the effectiveness of these drugs in reducing morbidity and mortality in asymptomatic and symptomatic patients. Unless absolutely contraindicated, ACE inhibitor therapy should be considered a priority. There are six strategies that will help extend the benefits of angiotensin-converting enzyme inhibitors in the management of heart failure: initiating treatment and ensuring good patient compliance, treating patients sooner, adding treatments, optimising the dose, eliminating confounding treatments and examining new disease areas. | |
Deskriptorji | ANGIOTENSIN-CONVERTING ENZYME INHIBITORS HEART FAILURE, CONGESTIVE PRACTICE GUIDELINES CONTROLLED CLINICAL TRIALS |